ترجمة وتحليل المصطلحات والاختصارات الطبية Abbreviations

Abbreviations and acronyms

ACC/AHA

American College of Cardiology/American Heart Association

ACCF/AHA

American College of Cardiology Foundation/American Heart Association

ACE

angiotensin-converting enzyme

ACEI

angiotensin-converting enzyme inhibitor

ACS

acute coronary syndrome

AF

atrial fibrillation

AHF

acute heart failure

AHI

apnoea/hypopnoea index

AIDS

acquired immunodeficiency syndrome

AKI

acute kidney injury

Aldo-DHF

aldosterone receptor blockade in diastolic heart failure

AL

amyloid light chain

ALT

alanine aminotransferase

AMI

acute myocardial infarction

AMICA

Atrial fibrillation Management In Congestive heart failure with Ablation

ANP

A-type natriuretic peptide

ANS

autonomic nervous system

ARB

angiotensin receptor blocker

ARNI

angiotensin receptor neprilysin inhibitor

ARVC

arrhythmogenic right ventricular cardiomyopathy

AST

aspartate aminotransferase

ASV

assisted servo-ventilation

ATLAS

Assessment of Treatment with Lisinopril And Survival

ATTR

transthyretin-mediated amyloidosis

AV

atrio-ventricular

AVP

arginine vasopressin

b.i.d.

bis in die (twice daily)

BioPACE

Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization

BiPAP

bilevel positive airway pressure

BiVAD

biventricular assist device

BLOCK-HF

Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrio-ventricular Block

BMI

body mass index

BNP

B-type natriuretic peptide

BP

blood pressure

bpm

beats per minute

BSA

body surface area

BTB

bridge to bridge

BTC

bridge to candidacy

BTD

bridge to decision

BTR

bridge to recovery

BTT

bridge to transplantation

BUN

blood urea nitrogen

CABANA

Catheter ABlation versus ANtiarrhythmic drug therapy for Atrial fibrillation

CABG

coronary artery bypass graft/grafting

CAD

coronary artery disease

CARE-HF

CArdiac REsynchronization in Heart Failure

CASTLE-AF

Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular dysfunction and Atrial Fibrillation

CCB

calcium-channel blocker

CCM

cardiac contractility modulation

CCS

Canadian Cardiovascular Society

CCU

coronary care unit

CHA₂DS₂-VASc

Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)

CHARM-Alternative

Candesartan in heart failure assessment of reduction in mortality and morbidity

CHARM-Added

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity

CHARM-Preserved

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity

CI

cardiac index

CI-AKI

contrast-induced acute kidney injury

CIBIS II

Cardiac Insufficiency Bisoprolol Study II

CK

creatine kinase

CKD

chronic kidney disease

CK-MB

creatine kinase MB

CMP

cardiomyopathy

CMR

cardiac magnetic resonance

COMPANION

Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure

CONFIRM-HF

Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure

CONSENSUS

Cooperative North Scandinavian Enalapril Survival Study

COPD

chronic obstructive pulmonary disease

COPERNICUS

Carvedilol Prospective Randomized Cumulative Survival

COX-2 inhibitor

cyclooxygenase-2 inhibitor

CPAP

continuous positive airway pressure

CPG

Committee for Practice Guidelines

CRT

cardiac resynchronization therapy

CRT-D

defibrillator with cardiac resynchronization therapy

CRT-P

pacemaker with cardiac resynchronization therapy

CSA

central sleep apnoea

CSR

Cheyne-Stokes respiration

CT

computed tomography

CYP3A4

cytochrome P450 3A4

DCM

dilated cardiomyopathy

DES

desmin

DHA

docosahexaenoic acid

DIG-PEF

ancillary Digitalis Investigation Group trial

DNA

deoxyribonucleic acid

DOSE

Diuretic Optimization Strategies Evaluation

DPD

3,3-diphosphono-1,2-propanodicarboxylic acid

DPP4i

dipeptidyl peptidase-4 inhibitor

DT

destination therapy

e′

early diastolic tissue velocity

ECG

electrocardiogram

Echo-CRT

Echocardiography Guided Cardiac Resynchronization Therapy

ECLS

extracorporeal life support

ECMO

extracorporeal membrane oxygenation

ED

emergency department

EF

ejection fraction

eGFR

estimated glomerular filtration rate

EHRA

European Heart Rhythm Association

EMA

European Medicines Agency

EMB

endomyocardial biopsy

EMF

endomyocardial fibrosis

EMPHASIS-HF

Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure

EPA

eicosapentaenoic acid

EPHESUS

Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

ESC

European Society of Cardiology

EU

European Union

EULAR

European League Against Rheumatism

Ex-DHF

Exercise training in Diastolic Heart Failure

FACIT-Pal

Functional Assessment of Chronic Illness Therapy - Palliative Care

FAIR-HF

Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure

FCM

ferric carboxymaltose

FiO₂

fraction of inspired oxygen

GFR

glomerular filtration rate

GGTP

gamma-glutamyl transpeptidase

GH

growth hormone

GLS

global longitudinal strain

GLP-1

glucagon-like peptide 1

HAS-BLED

Hypertension, Abnormal renal/liver function (1 point each), Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (1 point each)

HbA1c

glycated haemoglobin

HCM

hypertrophic cardiomyopathy

HES

hypereosinophilic syndrome

HF

heart failure

HFA

Heart Failure Association

HFmrEF

heart failure with mid-range ejection fraction

HFpEF

heart failure with preserved ejection fraction

HFrEF

heart failure with reduced ejection fraction

H-ISDN

hydralazine and isosorbide dinitrate

HIV/AIDS

human immunodeficiency virus/acquired immune deficiency syndrome

HR

heart rate

Hs troponin

high sensitivity troponin

IABP

intra-aortic balloon pump

IABP-SHOCK

IntraAortic Balloon Pump in Cardiogenic Shock

IABP-SHOCK II

IntraAortic Balloon Pump in Cardiogenic Shock II

ICD

implantable cardioverter-defibrillator

ICU

intensive care unit

IHD

ischaemic heart disease

IL

interleukin

INH

Interdisciplinary Network for Heart Failure

INTERMACS

Interagency Registry for Mechanically Assisted Circulatory Support

IN-TIME

Implant-based multiparameter telemonitoring of patients with heart failure

IPD

individual patient data

I-PRESERVE

Irbesartan in Heart Failure with Preserved Ejection Fraction Study

i.v.

intravenous

IVC

inferior vena cava

IVRT

isovolumetric relaxation time

KCCQ

Kansas City Cardiomyopathy Questionnaire

LA

left atrial/atrium

LAE

left atrial enlargement

LAVI

left atrial volume index

LBBB

left bundle branch block

LGE

late gadolinium enhancement

LMNA

lamin A/C

LMWH

low-molecular-weight heparin

LV

left ventricular/left ventricle

LVAD

left ventricular assist device

LVEDP

left ventricular end diastolic pressure

LVEDV

left ventricular end diastolic volume

LVEF

left ventricular ejection fraction

LVESV

left ventricular end systolic volume

LVID

left ventricular internal dimension

LVMI

left ventricular mass index

LVSD

left ventricular systolic dysfunction

MADIT-CRT

Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy

MCS

mechanical circulatory support

MERIT-HF

Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure

MR

mineralocorticoid receptor/magnetic resonance

MRA

mineralocorticoid receptor antagonist

MR-proANP

mid-regional pro A-type natriuretic peptide

MV

mitral valve

MV A-Wave

mitral valve late diastolic flow

MV E-Wave

mitral valve early diastolic flow

MYBPC3

cardiac myosin binding protein C

MYH7

cardiac β-myosin heavy chain

n-3 PUFA

n-3 polyunsaturated fatty acid

NEP

neprilysin

NOAC

non-vitamin K antagonist oral anticoagulant

NP

natriuretic peptide

NPPV

non-invasive positive pressure ventilation

NSAID

non-steroidal anti-inflammatory drug

NSTE-ACS

non-ST elevation acute coronary syndrome

NT-proBNP

N-terminal pro-B type natriuretic peptide

NYHA

New York Heart Association

o.d.

omne in die (once daily)

OMT

optimal medical therapy

OSA

obstructive sleep apnoea

PaCO₂

partial pressure of carbon dioxide in arterial blood

PAH

pulmonary arterial hypertension

PaO₂

partial pressure of oxygen in arterial blood

PARADIGM-HF

Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

PARAMOUNT

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

PCI

percutaneous coronary intervention

PCWP

pulmonary capillary wedge pressure

PDE5I

phosphodiesterase 5 inhibitor

Peak VO₂

peak oxygen uptake

PEP-CHF

Perindopril in Elderly People with Chronic Heart Failure

PET

positron emission tomography

PLN

phospholamban

PPV

positive pressure ventilation

PRISMA 7

seven-item, self-completion questionnaire to identify older adults with moderate to severe disabilities

PROTECT II

Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non Emergent High Risk PCI

PS-PEEP

pressure-support positive end-expiratory pressure

PV

pulmonary vein

PVR

pulmonary vascular resistance

QALY

quality-adjusted life year

QRS

Q, R, and S waves (combination of three of the graphical deflections)

RA

right atrium/atrial

RAAS

renin–angiotensin–aldosterone system

RAFT

Resynchronization-Defibrillation for Ambulatory Heart Failure Trial

RALES

Randomized Aldactone Evaluation Study

RCT

randomized controlled trial

RELAX

Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure

REVERSE

REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction

RV

right ventricular/ventricle

RVAD

right ventricular assist device

SADHART

Sertraline Antidepressant Heart Attack Randomized Trial

SAVE

Survival After Veno-arterial ECMO

SBP

systolic blood pressure

SCD-HeFT

Sudden Cardiac Death in Heart Failure Trial

SDB

sleep-disordered breathing

SENIORS

Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure

SERVE-HF

Treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive Servo-ventilation in patients with chronic heart failure

SHIFT

Systolic Heart failure treatment with the I_f inhibitor ivabradine Trial

SIGNIFY

Study Assessing the Morbidity–Mortality Benefits of the I_f Inhibitor Ivabradine in Patients with Coronary Artery Disease

SOLVD

Studies of Left Ventricular Dysfunction

SPECT

single-photon emission computed tomography

SpO₂

transcutaneous oxygen saturation

SPPB

Short Physical Performance Battery

SPRINT

Systolic Blood Pressure Intervention Trial

STEMI

ST segment elevation myocardial infarction

STICH

Surgical Treatment for Ischemic Heart Failure

STS

structured telephone support

TAPSE

tricuspid annular plane systolic excursion

TAVI

transaortic valve implantation

TDI

tissue Doppler imaging

TECOS

Trial Evaluating Cardiovascular Outcomes with Sitagliptin

TEHAF

Telemonitoring in Patients with Heart Failure

Tele-HF

Telemonitoring to Improve Heart Failure Outcomes

TIA

transient ischaemic attack

TIBC

total iron-binding capacity

t.i.d.

ter in die (three times a day)

TIM-HF

Telemedical Interventional Monitoring in Heart Failure

TOE

transoesophageal echocardiography

TOPCAT

Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist

TR

tricuspid regurgitation

TRV

tricuspid regurgitation velocity

TSAT

transferrin saturation

TSH

thyroid-stimulating hormone

TTE

transthoracic echocardiography

TTN

titin

ULT

urate lowering therapy

VAD

ventricular assist device

Val-HeFT

Valsartan Heart Failure Trial

VE-VCO₂

ventilatory equivalent ratio for carbon dioxide

VT

ventricular tachycardia

VV interval

interventricular pacing interval

WBC

white blood cells

WISH

Weight Monitoring in Patients with Severe Heart Failure

WRF

worsening renal function

Share on Google Plus

About محمد يونس الغادي

د.عمار خليل : أخصائي أمراض الباطنة العامة ( ماجستير القصر العيني ) وعضو الجمعية المصرية للتعليم الطبي المستمر والجمعية المصرية للسكر ودهنيات الدم، نتابع أمراض الكبد والجهاز الهضمي ، أمراض القلب وضغط الدم